Today’s Stock Alert: What Next for Flex Pharma Inc Stock After Making All-Time Low?

Today's Stock Alert: What Next for Flex Pharma Inc Stock After Making All Time Low?

The stock of Flex Pharma Inc (NASDAQ:FLKS) reached all time low today, Oct, 31 and still has $4.29 target or 12.00% below today’s $4.88 share price. This indicates more downside for the $81.42M company. This technical setup was reported by If the $4.29 PT is reached, the company will be worth $9.77 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 69,513 shares traded hands. Flex Pharma Inc (NASDAQ:FLKS) has declined 57.84% since March 29, 2016 and is downtrending. It has underperformed by 61.31% the S&P500.

Analysts await Flex Pharma Inc (NASDAQ:FLKS) to report earnings on November, 2. They expect $-0.80 EPS, down 50.94% or $0.27 from last year’s $-0.53 per share. After $-0.71 actual EPS reported by Flex Pharma Inc for the previous quarter, Wall Street now forecasts 12.68% negative EPS growth.

Flex Pharma Inc (NASDAQ:FLKS) Ratings Coverage

Out of 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Flex Pharma has been the topic of 3 analyst reports since August 21, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Zacks given on Wednesday, September 2. The stock of Flex Pharma Inc (NASDAQ:FLKS) has “Hold” rating given on Friday, October 14 by Cantor Fitzgerald. Zacks downgraded Flex Pharma Inc (NASDAQ:FLKS) on Friday, August 21 to “Hold” rating.

According to Zacks Investment Research, “Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.”

More notable recent Flex Pharma Inc (NASDAQ:FLKS) news were published by: which released: “/quotes/zigman/3870025/realtime” on January 28, 2015, also with their article: “News Flex Pharma Inc.FLKS” published on January 24, 2015, published: “Boston’s Flex Pharma raises $86.4 million in IPO” on January 29, 2015. More interesting news about Flex Pharma Inc (NASDAQ:FLKS) were released by: and their article: “Flex Pharma Announces FLX-787 as Clinical Drug Candidate” published on November 10, 2015 as well as‘s news article titled: “Flex Pharma Announces Scientific Advisory Board Appointment and Management Change” with publication date: August 26, 2016.

FLKS Company Profile

Flex Pharma, Inc., incorporated on February 26, 2014, is a biotechnology firm that is developing treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Firm operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s product candidates are based on the mechanism of action described as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, is translated into a neuronal sensory signal that produces a beneficial effect. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing products using TRP activators.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment